首页 | 本学科首页   官方微博 | 高级检索  
检索        

黄芪多糖体外对慢性粒细胞白血病患者治疗前后浆细胞样树突细胞功能及成熟的影响
作者姓名:Liu LM  Zhang LS
作者单位:1. 徐州医学院附属淮安医院、淮安市第二人民医院血液科,223002
2. 兰州大学第二医院血液科,730030
摘    要:目的 通过体外实验研究黄芪多糖(APS)对浆细胞样树突细胞(pDC)功能及成熟的影响,进一步阐明APS洞节免疫的作用.方法 从初诊未治及缓解期慢性粒细胞白血病(CML)患者外周血分选pDC,分别加入0、50、100、200 mg/L的APS共孵育,24 h后收集上清液,用ELISA法检测pDC的IFN-α、IL-6、TNF-α分泌水平,5 d后收集细胞,用流式细胞术检测DC免疫表型,光学显微镜下观察DC的形态,扫描电镜下观察DC的超微结构.结果 APS可显著提高CML缓解期患者pDC IFN-α、IL-6、TNF-α分泌水平100 mg/L APS处理24 h与未加药组相比分别为(613±44)对(478±33)、(180±41)对(99±22)、(210±37)对(166±29)ng/L]及初诊未治患者pDC IL-6、TNF-α分泌水平100 mg/LAPS处理24 h,与未加药组相比分别为(38±7)对(21±5)和(84±20)对(66±19)ng/L],并呈APS浓度依赖性(P<0.05);APS可促进CML患者pDC向DC分化和成熟,并呈APS浓度依赖性(P<0.05).结论 APS能够增强CML患者pDC的功能,并促进其向DC的分化和成熟.

关 键 词:黄芪多糖  白血病  髓样  慢性  树突细胞

Effect of astragalus polysaccharide on the function and maturation of plasmacytoid dendritic cells from chronic myelogenous leukemia before and after treatment
Liu LM,Zhang LS.Effect of astragalus polysaccharide on the function and maturation of plasmacytoid dendritic cells from chronic myelogenous leukemia before and after treatment[J].Chinese Journal of Hematology,2010,31(11):740-743.
Authors:Liu Li-Min  Zhang Lian-Sheng
Institution:Department of Hematology, Second People Hospital of Lanzhou University, Lanzhou 730030, China.
Abstract:Objective To explore the effect of astragalus polysaccharide (APS) on the function and maturation of chronic myelogenous leukemia (CML) peripheral blood mononuclear cells ( PBMC ) -derived plasmacytoid dendritic cells (pDCs). Methods CML-derived pDCs were sorted by flow cytometry, and then incubated with APS ( at 0,50,100 and 200 mg/L). After 24 hours, the concentrations of IFN-α, IL-6 ,TNF-α were detected with ELISA. Five days later, the cultured cells were collected and analyzed for immotype, morphology and ultramicrostructure. Results The level of IFN-α, IL-6,TNF-α was significantly higher in samples from CML remission group than that in untreated pDCs, and newly diagnosed pDC ( P < 0.05 ) or untreated group. APS could promote more pDCs differentiating to dendritic cells (DCs) in CML remission group than in untreated-pDCs in a dose-dependant manner ( P < 0.05 ). Conclusion APS can enhance the immune function of pDCs, promote differentiation and maturation of pDCs from CML patients.
Keywords:Astragalus polysaccharide  Leukemia  myelocytic chronic  Plasmacytoid dendritic cells  Immunotherapy
本文献已被 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号